Most "best longevity drugs" lists rank by popularity. This one ranks by what's actually been measured in trials — and several popular compounds rank lower than you'd expect.
Ranking is by Geroevidence's four-tier evidence ladder — Strong, Moderate, Emerging, Insufficient — based on trial volume and outcome type, not on what's trending. This list does not constitute a recommendation to use any of these compounds; it's a structured summary of where the published evidence currently stands.
Taurine, berberine, spermidine, Urolithin A, and fisetin currently lack the minimum published human trial or strong ITP-style data Geroevidence requires for a formal tier. That doesn't mean "no evidence" — several have promising mouse or Phase II signals — it means the human evidence base hasn't yet crossed the threshold. See each compound's full profile for current status.
The compounds with the most online attention — NMN, senolytics, taurine — are not the ones with the strongest published evidence. The two interventions with genuine Phase III outcome data, GLP-1 agonists and SGLT2 inhibitors, are approved drugs for diabetes and weight management first, longevity-adjacent second. That asymmetry between hype and evidence is exactly what this ranking is built to surface.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.